⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 25, 2025SHILAP Revista de lepidopterologíaOpen Access

Ruxolitinib cream monotherapy for facial and/or neck atopic dermatitis: results from a decentralized, randomized phase 2 clinical trial

Zelma C. Chiesa Fuxench Zhihong Lai YuTzu Kuo Haq Nawaz Jonathan Cotliar

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Ruxolitinib cream improved signs and symptoms of facial/neck AD vs vehicle and was well tolerated.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fuxench et al. (2025) studied this question.

synapsesocial.com/papers/69dc2a648bac30e30e9f536e https://doi.org/10.1080/09546634.2025.2480744

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1625 - Efficacy and safety of 1.5% ruxolitinib cream in patients with facial and/or neck atopic dermatitis: a randomized, double-blind, decentralized phase 2 study2024
2Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind studyRCT · 2025 · 23 citations
3Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trialRCT · 2026
4Ruxolitinib Cream As-Needed Monotherapy Demonstrates Sustained Disease and Symptom Control in Patients with Mild to Moderate Atopic Dermatitis: Pooled Analysis from Two Phase 3 StudiesMeta-Analysis · 2026 · 1 citations
5Ruxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis.2025 · 1 citations